Blood vessel invasion is a major prognostic factor in resected non-small cell lung cancer

Kessler, Romain; Gasser, Bernard; Massard, Gilbert; Roeslin, N; Meyer, P.; Wihlm, Jean‐Marie; Morand, G

doi:10.1016/0003-4975(96)00540-1

Cited by 77 publications

(49 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…patients, including stage I patients, who have undergone radical resection (Ichinose et al, 1994;Kessler et al, 1996;Duarte et al, 1998;Port et al, 2003;Gabor et al, 2004;Sakao et al, 2004); the frequency of radical resection generally ranges from 15 to 36% in the literature (Rigau et al, 2002;Funai et al, 2011). In our research, we retrospectively studied the follow-up records of stage I NSCLC patients to analyze the relationship between LVI and prognosis.…”

Section: Discussionmentioning

confidence: 98%

Clinical significance of lymphatic vessel invasion in stage I non-small cell lung cancer patients

Ma¹,

Chu²,

Liu³

2015

Genet. Mol. Res.

View full text Add to dashboard Cite

ABSTRACT. The aim of this retrospective study was to evaluate the prognostic influence of lymphatic vessel invasion (LVI) in stage I non-small cell lung cancer (NSCLC) patients. From January 2004 to December 2007, LVI was detected in 57 patients with T1N0M0 NSCLC; therefore, 114 patients with the same pathology, T stage, and surgery method, but without LVI, were selected as the control group to compare survival. The overall survival and relapse-free survival rates were estimated using the Kaplan-Meier method, log-rank test, and Cox proportional hazards analysis. The average follow-up length was 59.94 ± 23.1 months. The 5-year overall survival rates of the LVI-negative and the LVI-positive groups were 90.54 and 70.1%, respectively (P = 0.002). A multivariate analysis revealed LVI to be an independent predictive factor (hazard ratio = 4.562; P = 0.004). The 5-year overall survival rates for patients who received postoperative adjunctive therapy and those who did not in the LVI-positive group were 88.2 and 61.5%, respectively, with a P value less than 0.05 in both univariate and multivariate analyses. LVI is a poor prognostic factor in stage I NSCLC patients; postoperative adjunctive therapy is needed to improve the 1820 K.F. Ma et al.

show abstract

Section: Discussionmentioning

confidence: 98%

Clinical significance of lymphatic vessel invasion in stage I non-small cell lung cancer patients

Ma¹,

Chu²,

Liu³

2015

Genet. Mol. Res.

View full text Add to dashboard Cite

show abstract

“…Vascular invasion is associated with unfavorable prognosis in NSCLC (Bodendorf et al 2009;Gabor et al 2004;Kessler et al 1996;Miyoshi et al 2009;Poncelet et al 2008;Rigau et al 2002). We previously reported that vascular invasion could be classified as intratumoral or extratumoral, according to its location (Maeda et al 2010).…”

Section: Discussionmentioning

confidence: 99%

Interstitial growth as an aggressive growth pattern in primary lung cancer

Suzuki

Aokage

Hishida

et al. 2016

J Cancer Res Clin Oncol

View full text Add to dashboard Cite

show abstract

“…Blood vessel invasion has been inconsistently shown to have prognostic significance in early-stage lung cancer, although two studies [28,29] have provided data supporting the concept that the absence of blood vessel invasion identifies a group of patients with a very low probability of distant metastasis.…”

Section: Surgical Management Of T1n0m0 and T2n0m0 Lung Cancermentioning

confidence: 99%

Current surgical treatment of nonsmall cell lung cancer 2001

Deslauriers¹

2002

Eur Respir J

View full text Add to dashboard Cite

Recognizing that surgical treatment is still the best option for controlling lung cancer, surgeons want an operation to be performed when the benefits clearly outweigh the possible risks, and when it has been determined that cancer resection is the most appropriate course of management. The necessity for a compulsive attitude toward preoperative assessment is therefore to be emphasized.Approximately 45% of all lung cancers are limited to the chest, where surgical resection is the most effective method of controlling the disease. Patients with tumour (T) 1, node (N) 0 and T2N0 tumours have early lung cancer, and most are curable by resection, with 5-yr survival rates in the range 75-80% for patients with T1N0 status. The "gold standard" of surgery remains lobectomy. Stage T1N1 and T2N1 carcinomas represent a group of patients in whom the disease involves hilar and bronchopulmonary nodes. This group is best treated by complete resection and mediastinal lymphadenectomy.Survival data following surgical resection of T3 tumours clearly show better survival in patients with T3N0 disease than in those with T3N1-2 disease. Five-year survival rates for completely resected T3N0 lesions are in the range 30-50%. Once N1 disease is present, survival decreases to 15-20%. Incomplete resections fail to cure and surgery is not indicated if N2 disease is documented preoperatively. On occasion, T4 tumours involving the carina or vertebral body can be completely resected but T4N1-2 lesions are virtually incurable by surgery.The presence of mediastinal lymph node metastasis (N2/N3 disease) is an ominous prognostic sign and stage III-b disease, by virtue of metastatic contralateral nodes, is an absolute contraindication to surgical resection. Induction treatments with chemoradiation have shown prolongation of survival and three randomized trials have demonstrated a survival advantage over surgery alone.

show abstract

Blood vessel invasion is a major prognostic factor in resected non-small cell lung cancer

Cited by 77 publications

References 14 publications

Clinical significance of lymphatic vessel invasion in stage I non-small cell lung cancer patients

Clinical significance of lymphatic vessel invasion in stage I non-small cell lung cancer patients

Interstitial growth as an aggressive growth pattern in primary lung cancer

Current surgical treatment of nonsmall cell lung cancer 2001

Contact Info

Product

Resources

About